S&P 5005,963+0.54%
NASDAQ21,443+0.87%
DOW43,892+0.31%
DAX23,888+0.44%
FTSE 1008,721-0.12%
EUR/USD1.1465+0.07%
GBP/USD1.3220+0.14%
USD/JPY161.31-0.03%
Gold3,241+0.22%
WTI Oil76.40+0.81%
Bitcoin103,241+1.43%
10Y UST4.47%-9bp
S&P 5005,963+0.54%
NASDAQ21,443+0.87%
DOW43,892+0.31%
DAX23,888+0.44%
FTSE 1008,721-0.12%
EUR/USD1.1465+0.07%
GBP/USD1.3220+0.14%
USD/JPY161.31-0.03%
Gold3,241+0.22%
WTI Oil76.40+0.81%
Bitcoin103,241+1.43%
10Y UST4.47%-9bp
MarketsFN
Home/Hedge Funds/Baker Bros Advisors/Q4 2020

Baker Bros Advisors

Period: Q4 2020 Β· Filed: 2021-02-16
View on SEC EDGAR β†—
AUM
$26.54B
Total portfolio value
Positions
126
Reported securities
Top Holding
SGEN
31.2% $8.28B
QoQ Changes
+8 / -8
new Β· exited
⚠️13F Filing Disclosure

AUM figures shown are calculated by summing the reported market value of all positions in SEC 13F-HR filings β€” not the fund's actual assets under management.

  • Excludes cash, bonds, private equity, short positions, and foreign-listed stocks not required to be reported.
  • For PUT and CALL options, the reported Value is the notional value of the underlying shares β€” not the option premium paid. This significantly overstates the actual capital at risk.
  • Actual fund AUM is typically higher and includes strategies, instruments, and positions that never appear in a 13F.
  • 13F filings cover institutional managers with β‰₯$100M in 13F securities. Positions reflect end-of-quarter holdings, disclosed up to 45 days after the period ends.

Data sourced from SEC EDGAR. This tracker is for informational purposes only and does not constitute investment advice.

Portfolio Holdings

Top 30 positions

⚠️ Performance % calculated from filing date ( 2021-02-16) shown is the underlying stock price movement β€” not the derivative's P&L.
TickerIssuerNotionalPort %@ FilingNow (EOD)Since FilingAllocation
SGENSeagen Inc.$8.28B31.19%β€”β€”
31.2%
ONCBeiGene, Ltd.$3.02B11.36%$258.39$297.65+15.2%
11.4%
INCYIncyte Corporation$2.78B10.49%$86.98$116.86+34.4%
10.5%
ACADACADIA Pharmaceuticals Inc.$2.24B8.44%$53.46$25.97-51.4%
8.4%
KODKodiak Sciences Inc.$2.04B7.68%$146.91$38.54-73.8%
7.7%
ALXNAlexion Pharmaceuticals, Inc.$1.37B5.16%β€”β€”
5.2%
PRLDPrelude Therapeutics Incorporated$724.0M2.73%$71.55$4.91-93.1%
2.7%
BMRNBioMarin Pharmaceutical Inc.$665.5M2.51%$87.69$58.99-32.7%
2.5%
NVTAQInvitae Corporation$654.3M2.46%β€”β€”
2.5%
ASNDAscendis Pharma A/S$590.5M2.22%$166.78$274.50+64.6%
2.2%
ABCLAbCellera Biologics Inc.$420.5M1.58%$40.24$8.11-79.8%
1.6%
MRTXMirati Therapeutics, Inc.$309.6M1.17%β€”β€”
1.2%
ARGXargenx SE$299.8M1.13%$294.09$939.68+219.5%
1.1%
IGMSIGM Biosciences, Inc.$277.7M1.05%β€”β€”
1.1%
MDGLMadrigal Pharmaceuticals, Inc.$166.7M0.63%$111.17$528.10+375.0%
0.6%
AMRNXXXXAmarin Corporation plc$136.9M0.52%β€”β€”
0.5%
HRTXHeron Therapeutics, Inc.$126.9M0.48%$21.17$0.44-97.9%
0.5%
KYMRKymera Therapeutics, Inc.$121.5M0.46%$62.00$113.51+83.1%
0.5%
ALLKAllakos Inc.$100.0M0.38%β€”β€”
0.4%
CERSCerus Corporation$94.9M0.36%$6.92$3.16-54.3%
0.4%
BCRXBioCryst Pharmaceuticals, Inc.$94.6M0.36%$7.45$9.84+32.1%
0.4%
PACBPacific Biosciences of California, Inc.$83.1M0.31%$25.94$1.68-93.5%
0.3%
ZYMEZymeworks Inc.$80.7M0.30%$47.26$26.31-44.3%
0.3%
INSMInsmed Incorporated$71.8M0.27%$33.29$111.60+235.2%
0.3%
FMTXForma Therapeutics Holdings, Inc.$70.7M0.27%β€”β€”
0.3%
RYTMRhythm Pharmaceuticals, Inc.$68.8M0.26%$29.73$114.17+284.0%
0.3%
NBIXNeurocrine Biosciences, Inc.$64.9M0.24%$95.85$174.26+81.8%
0.2%
AXSMAxsome Therapeutics, Inc.$63.5M0.24%$81.47$244.31+199.9%
0.2%
RAREUltragenyx Pharmaceutical Inc.$61.5M0.23%$138.43$33.47-75.8%
0.2%
NRIXNurix Therapeutics, Inc.$58.8M0.22%$32.88$23.97-27.1%
0.2%

Quarter-on-Quarter Activity

Q4 2020 vs. Q3 2020

New Positions (8)

TickerIssuerNotionalSince Filing
ABCLAbCellera Biologics Inc.$420.5M-79.8%
RAREUltragenyx Pharmaceutical Inc.$61.5M-75.8%
ALGSAligos Therapeutics, Inc.$44.5M
OPTEYOpthea Limited$37.1M
BCABBioAtla, Inc.$28.1M
VSTMXXXXVerastem, Inc.$21.6M
MREOMereo BioPharma Group plc$21.6M
KDNYChinook Therapeutics, Inc.$11.9M

Exited Positions (8)

TickerIssuerNotional
MYOKMyoKardia, Inc.$410.3M
EXASExact Sciences Corporation$188.2M
Neurocrine Biosciences, Inc.$42.3M
IMMUImmunomedics, Inc.$20.2M
UROVUrovant Sciences Ltd.$9.1M
CPRXCatalyst Pharmaceuticals, Inc.$1.4M
APLTApplied Therapeutics, Inc.$0.8M
ARAVAravive, Inc.$0.4M

Increased (8)

TickerIssuerNotionalShares Ξ”
GTHGenetron Holdings Limited$5.2M+355.3%
RETAReata Pharmaceuticals, Inc.$22.5M+321.1%
GMDAQGamida Cell Ltd.$10.4M+144.5%
CRNXCrinetics Pharmaceuticals, Inc.$4.0M+103.9%
IMTXImmatics N.V.$8.8M+80.2%
AUTLAutolus Therapeutics plc$1.6M+69.6%
OVIDOvid Therapeutics Inc.$-1.2M+61.8%
ADAPYAdaptimmune Therapeutics plc$2.5M+55.3%

Trimmed (8)

TickerIssuerNotionalShares Ξ”
QUREuniQure N.V.$-6.9M-96.5%
KZRKezar Life Sciences, Inc.$-2.0M-75.7%
HRMYHarmony Biosciences Holdings, Inc.$-7.0M-55.0%
GNFTYGenfit SA$-0.1M-48.2%
RCUSArcus Biosciences, Inc.$-0.1M-37.0%
CCXIChemoCentryx, Inc.$-8.7M-27.0%
REPLReplimune Group, Inc.$1.1M-25.7%
ALBOAlbireo Pharma, Inc.$-2.9M-24.9%
← Back to Hedge Funds